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  Siglec-9 is a sialic acid binding lectin predominantly expressed on myeloid 19	  
cells. Aberrant glycosylation occurs in essentially all types of cancers 20	  
resulting in increased sialylation. Thus when MUC1 is expressed on cancer 21	  
cells it is decorated by multiple short, sialylated O-linked glycans (MUC1-ST). 22	  
Here we show that this cancer-specific MUC1 glycoform could, through the 23	  
engagement of Siglec-9, educate myeloid cells to release factors associated 24	  
with tumor microenvironment determination and disease progression. 25	  
Moreover MUC1-ST induced macrophages to display a TAM-like phenotype 26	  
with increased expression of PD-L1. MUC1-ST binding to Siglec-9 did not 27	  
activate SHP-1/2 but surprisingly induced calcium flux leading to MEK-ERK 28	  
activation. This work defines a critical role for aberrantly glycosylated MUC1 29	  
and identifies an activating pathway following Siglec-9 engagement. 30	  31	  
	  Cancers have developed a plethora of mechanisms to evade the immune response 32	  
including initiating a permissive local environment. For cancer cells to remodel their 33	  
microenvironment they need to acquire changes that include the recruitment and 34	  
education of monocytes, and the repolarization of resident macrophages1. 35	  
Macrophages are phenotypically plastic and factors produced by cancer cells can 36	  
polarize macrophages to become tumor-promoting. These tumor-educated 37	  
macrophages promote the growth and invasion of cancer cells by contributing to all 38	  
the stages involved in cancer dissemination, cumulating in metastasis2  39	  
 40	  
Changes in glycosylation occur in essentially all types of cancers and changes in 41	  
mucin-type O-linked glycans are the most prevalent aberrant glycophenotype when 42	  
increased sialylation often occurs3,4. The transmembrane mucin MUC1 is 43	  
upregulated in breast and the majority of adenocarcinomas and, due to the presence 44	  
of a variable number of tandem repeats that contain the O-linked glycosylation sites, 45	  
can carry from 100 to over 750 O-glycans5. The aberrant glycosylation seen in 46	  
cancer results in the multiple O-linked glycans carried by MUC1 being mainly short 47	  
and sialylated3,6, in contrast to the long, branched chains seen on MUC1 expressed 48	  
by normal epithelial cells7. In carcinomas the aberrant O-linked glycosylation of 49	  
MUC1 can alter the interaction of MUC1 with lectins of the immune system8 and 50	  
thereby influence tumor-immune interplay. While it is clear that expression of MUC1 51	  
carrying short, sialylated core 1 glycans (NeuAcα2,3Galβ1-3GalNAc; MUC1-ST) 52	  
enhances tumor growth9,10, the mechanisms underlying this increased growth are ill-53	  
defined.  However, the immune system appears to play a role as syngeneic mouse 54	  
tumor cells expressing MUC1-ST grow significantly faster in MUC1-transgenic mice 55	  
than the same cells expressing MUC1 carrying branched core 2 glycans associated 56	  
with normal glycosylation, while this differential growth is not seen in 57	  
immunosuppressed mice9. 58	  
 59	  
Siglecs (sialic acid-binding immunoglobulin-like lectins) are a family of sialic acid 60	  
binding lectins, which, with the exception of Siglec-4, are expressed on various cells 61	  
of the immune system11. The cytoplasmic domains of most Siglecs contain 62	  
immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which recruit the tyrosine 63	  
phosphatases, SHP-1 and/or SHP-2 (ref. 12) and so regulate the cells of the innate 64	  
and adaptive immune response13. It has recently become clear that Siglecs play a 65	  
role in cancer immune suppression, the hypersialylation seen in cancers inducing 66	  
binding to these lectins14-16. MUC1 expressed by cancer cells has been shown to 67	  
bind to Siglec-9 resulting in the recruitment of β-catenin to the cytoplasmic tail of 68	  
	  MUC1 inducing its translocation to the nucleus and increased tumor cell growth17. 69	  
This work focused on the effect of the interaction with Siglec-9 on the MUC1 70	  
expressing cancer cells. In contrast we have investigated the effect of the interaction 71	  
on the Siglec-9 expressing immune cells using a defined glycoform of MUC1 (ref. 18). 72	  
Siglec-9 is predominantly expressed on myeloid cells and has a preference for sialic 73	  
acid α2,3 linked to galactose19. Here we show that MUC1 carrying the sialylated core 74	  
1 glycan (MUC1-ST) a glycan not found on this mucin expressed by normal epithelial 75	  
cells, binds to Siglec-9 on primary human monocytes and macrophages, and induces 76	  
a unique secretome signature from each cell type. Moreover, when MUC1-ST binds 77	  
to Siglec-9 expressed by primary macrophages a tumor-associated macrophage 78	  
(TAM) phenotype is actively induced shown by the inhibition of CD8+ T cell 79	  
proliferation and the upregulation of IDO (indoleamine 2,3-dioxygenase), CD163, 80	  
CD206 and of the checkpoint ligand PD-L1 (programmed death ligand 1). 81	  
 82	  
Results 83	  
 84	  
MUC1-ST binds to Siglec-9 expressed by myeloid cells 85	  
To investigate the interaction of MUC1-ST with cells of the immune system, immune 86	  
cell subsets were isolated from donor blood and incubated with biotinylated purified 87	  
recombinant tumor-associated MUC1 glycoforms18 (Fig. 1a and Supplementary Fig. 88	  
1a). MUC1 carrying sialylated core-1 glycans (NeuAcα2,3Galβ1-3GalNAc; MUC1-89	  
ST), bound to primary monocytes and macrophages and acute myeloid leukemia 90	  
(AML) lines (Fig. 1a–e). This interaction was lost upon neuraminidase treatment of 91	  
MUC1-ST to give MUC1-T, demonstrating that the binding was dependent upon 92	  
sialic acid (Fig. 1b–d). The binding also increased with time, maximum binding 93	  
occurring at 5 hours, and with increased the concentration of MUC1-ST  94	  
(Supplementary Fig. 1b,c) but was calcium independent (Fig. 1f). Moreover, the 95	  
binding was enhanced when cells were pre-treated with neuraminidase 96	  
(Supplementary Fig. 1d), which removes competing cis-binding sialic acid sites 97	  
from the surface of the cells. This pattern is characteristic of binding to Siglec 98	  
molecules11 and indeed MUC1-ST bound recombinant Siglecs-3, 7, 9 and 10; with 99	  
the greatest binding seen for Siglec-9 (Fig. 1g).  Although Siglecs-3, 7 and 9 are 100	  
expressed by monocytes and macrophages (Supplementary Fig.1e), a blocking 101	  
antibody to Siglec-9 inhibited 80-95% of the MUC1-ST binding to these cells (Fig. 102	  
1h,i; Supplementary Fig. 1f, Supplementary Table 1) indicating this is the 103	  
dominant binding Siglec. It should be noted that this anti-Siglec-9 antibody can also 104	  
	  act as an activating antibody as it recognizes the sialic acid binding site on Siglec-921, 105	  
Importantly, Siglec-9 bound to the breast cancer cell line T47D that expresses MUC1 106	  
carrying sialylated core-1 glycans (Fig. 1j)20. However, a multivalent polymer of 107	  
sialylated core 1 glycans bound only weakly to monocytes and this interaction could 108	  
not be inhibited with anti-Siglec-9 (Supplementary Fig.1g).  This finding suggests a 109	  
contribution of the protein backbone to the binding specificity of Siglec-9, possibly by 110	  
defining a specific spacing of the sialic acids. Thus MUC1-ST specifically binds to 111	  
Siglec-9 on primary monocytes and macrophages. 112	  
 113	  
MUC1-ST binding induces the secretion of various factors 114	  
To determine whether MUC1-ST binding induced a cellular response, we assayed for 115	  
soluble factors released from cultured primary monocytes upon binding recombinant 116	  
MUC1-ST. MUC1-ST induced monocytes to secrete several factors associated with 117	  
inflammation and tumor progression (Fig. 2a and Supplementary Fig. 2a). We 118	  
validated the induced secretion of interleukin 6 (IL-6), macrophage colony-stimulating 119	  
factor (M-CSF)	   and plasminogen activator inhibitor-1 (PAI-1) by ELISA. Their 120	  
induction was dependent upon recognition of sialic acid, as MUC1 carrying non-121	  
sialylated core-1 (MUC1-T) failed to induce such secretion (Fig. 2b,c,d) in addition 122	  
blocking MUC1-ST binding using Siglec-9-specific antibody significantly decreased 123	  
the secretion of these three factors (Fig. 2e,f,g). Some of the factors that were 124	  
secreted upon MUC1-ST engagement of Siglec-9 have the potential to remodel the 125	  
microenvironment by recruiting monocytes and neutrophils (CXCL5, CCL2, CCL3, 126	  
CXCL1, IL-8 and PAI-1)22,23, to induce angiogenesis (PAI-1, IL-8)24,25 and to degrade 127	  
the extracellular matrix (MMP9, PAI-1)26. Monocytes incubated with the breast cancer 128	  
cell line T47D, which expresses MUC1-ST, also induced the release of PAI-1 129	  
(Fig.2h).  As a control, we used T47D cells that had been transfected with the 130	  
glycosyltransferase C2GnT1 (ref 20). C2GnT1 competes with the sialyltransferase 131	  
that forms the ST glycan, resulting in expression of MUC1 carrying branched core-2 132	  
glycans that are representative of the glycosylation of MUC1 by normal mammary 133	  
epithelial cells20. The secretion of PAI-1 was significantly reduced when these 134	  
transfected control cells were incubated with monocytes (Fig. 2h).   In response to 135	  
MUC1-ST, monocytes also produced pro-inflammatory nitric oxide (NO) (Fig. 2i), a 136	  
product of the arginine processing enzyme27. This release was partially reduced, 137	  
although not significantly because of donor variation, with the Siglec-9 antibody (Fig. 138	  
2i).  Thus Siglec-9 engagement by MUC1-ST induced the release of factors that can 139	  
promote tumor growth and modulate the microenvironment. 140	  
 141	  
	   142	  
MUC1-ST binding influences myeloid differentiation 143	  
As IL-6 and NO are known modulators of cellular differentiation28,29, we assessed the 144	  
effects of MUC1-ST on the differentiation of monocytes into macrophages or 145	  
dendritic cells. Monocytes were differentiated into macrophages with M-CSF for 146	  
seven days followed by lipopolysaccharide (LPS) and IFN-γ to give M(LPS+IFN-γ)30 147	  
(historically defined as M1-like macrophages).. When MUC1-ST was added at day 0 148	  
of the culture, the differentiated macrophages showed reduced surface expression of 149	  
the co-stimulatory molecule CD86 (Fig. 3a,b) and secreted of IL-12 was significantly 150	  
reduced by over 10 fold (Fig. 3c). These significant phenotypic changes could at 151	  
least be partially rescued by blocking antibodies to Siglec-9 or the IL-6 receptor (Fig. 152	  
3a-c). We induced primary monocytes to differentiate to macrophages in the 153	  
presence or absence of MUC1-ST and then cultured with autologous T cells, which 154	  
had been stimulated with anti-CD3 and anti-CD28. Proliferation of the CD8+ T cells, 155	  
as measured by the decrease in eFluor670 dye by flow cytometry, was significantly 156	  
inhibited when co-cultured with the macrophages differentiated from monocytes in 157	  
the presence of MUC1-ST compare to those culture with macrophages differentiated 158	  
from monocytes in the absence of MUC1-ST  (Fig.3d). Moreover, these CD8+ T cells 159	  
showed a lower level of activation as demonstrated by reduced expression of CD25 160	  
and CD69 (Fig. 3e,f). This inhibition of activation could be reversed by the presence 161	  
of antibodies against Siglec-9 or IL-6 receptor α (IL-6Rα) (Fig. 3f). The effect of the 162	  
anti-Siglec-9 might be explained by Siglec-9 being expressed on a subset of T cells19.  163	  
However, when monocytes were differentiated into macrophages in the presence of 164	  
MUC1-ST and anti-Siglec-9, and then cultured with autologous T cells stimulated 165	  
with anti-CD3 and anti-CD28, activation of the T cells was brought back to the 166	  
isotype control (Fig. 3f, middle).   167	  
 168	  
 169	  
Monocytes differentiated into immature dendritic cells (DCs) with IL-4 and 170	  
granulocyte-macrophage colony-stimulating factor (GM-CSF) in the presence of 171	  
MUC1-ST displayed less expression of CD86 as compared to those differentiated to 172	  
DCs in the absence of MUC1-ST (Supplementary Fig. 2b) and, when matured with 173	  
LPS expressed less CD86 and CD83 (Supplementary Fig. 2c), as observed 174	  
previously31. Antibodies to Siglec-9 and IL-6 significantly reversed this down-175	  
regulation of CD86 by immature and mature DCs (Supplementary Fig. 2d-f) and 176	  
partially reversed the down-regulation of CD83 by mature DCs (data not shown). 177	  
	  Thus, MUC1-ST binding to monocytes induces a pro-inflammatory phenotype that 178	  
can recruit immune cells into the tumor, induce the secretion of factors associated 179	  
with tumor progression and induce the differentiation of monocytes into macrophages 180	  
and dendritic cells with reduced CD8 stimulatory capacity.  181	  
 182	  
 183	  
MUC1-ST binding to macrophages induces a TAM phenotype 184	  
We assayed monocyte-derived macrophage secretion of proteins when these 185	  
macrophages were treated with MUC1-ST (Fig. 4a). Similar to monocytes, 186	  
macrophages increased secretion of M-CSF (Fig. 4b), PAI-1 (Fig. 4c) as well as the 187	  
protease chitinase 3-like-1 (CHI3L1) (Fig. 4a). In addition, secretion of epidermal 188	  
growth factor (EGF) was increased as compared to treatment of the macrophages 189	  
with MUC1-T or no MUC1 (Fig. 4d). Production of these factors associated with 190	  
tumor progression24 was dependent upon Siglec-9 (Fig. 4e,f,g), although changes in 191	  
EGF secretion were not significant due to donor variation. Importantly, as with 192	  
monocytes, we detected increased secretion of PAI-1 after co-culturing macrophages 193	  
with MUC1-ST-positive T47D cells (Fig. 4h). Moreover, when macrophages were 194	  
cultured with T47D cells expressing MUC1 carrying branched core 2 glycans20 (T47D 195	  
core 2), the secretion of PAI-1 was significantly reduced as compared to T47D-ST 196	  
(Fig. 4h). However, unlike MUC1-ST–treated monocytes, expression of chemokines 197	  
associated with immunomodulation and cytokines were decreased or did not change 198	  
(Fig. 4a). Thus, MUC1-ST, Siglec-9 ‘educated’ monocytes and macrophages display 199	  
unique secretomes.  200	  
 201	  
Compared to controls, MUC1-ST–treated macrophages showed increased 202	  
expression of mannose receptor (CD206) and the scavenger receptor CD163 (Fig. 203	  
5a). The expression of these makers is associated with tumor-associated 204	  
macrophages32. Moreover, increased expression of the immune checkpoint ligand 205	  
PD-L1 was observed (Fig. 5a), although only a minimal increase in PD-L2 was 206	  
observed (data not shown). These phenotypic changes could all be rescued by 207	  
blocking binding of MUC1-ST to macrophages with anti-Siglec-9 (Fig. 5a). In addition, 208	  
treatment of macrophages with MUC1-ST increased the expression of the mRNA 209	  
encoding indoleamine 2,3-dioxygenase (IDO) by 10-25 fold as compared to no 210	  
MUC1-ST (Fig. 5b,c), which also could be rescued using a Siglec-9 antibody. IDO 211	  
catalyzes the rate-limiting step in the metabolism of tryptophan and an increase in 212	  
the tryptophan metabolite kynurenine was seen when macrophages were treated 213	  
with MUC1-ST (Fig. 5d). The activity of IDO inhibits proliferation and induces 214	  
	  apoptosis of T cells33. Moreover increased expression of PD-L1 can engage the PD-1 215	  
receptor on activated T cells inhibiting their function34. Macrophages that had been 216	  
educated with MUC1-ST exhibited decreased ability to stimulate the proliferation and 217	  
IFN-γ secretion of allogeneic CD8+ T cells, with these effects being inhibited with the 218	  
Siglec-9 blocking antibody (Fig. 5e,f). To investigate the role of PD-L1 in the 219	  
inhibition of CD8+ T cell proliferation we used the PD-1 blocking antibody 220	  
pembrolizumab to inhibit the binding of PD-L1 to PD-1 on the T cells.  However, we 221	  
could not inhibit the reduction of T cell proliferation induced by MUC1-ST educated 222	  
macrophages (Fig.5g), nor could we rescue the decrease in IFN-γ observed when 223	  
the interaction of PD-L1 with PD-1 was inhibited with pembrolizumab (Fig. 5h). Thus, 224	  
in this in vitro system where the T cells are not responding to a specific antigen, PD-225	  
L1 does not contribute to the decrease in T cell proliferation induced by MUC1-ST–226	  
educated macrophages.  This MUC1-ST–induced profile of expression and functional 227	  
activity is indicative of tumor-associated macrophages (TAMs), which play a role in 228	  
promoting tumor progression35,36.  229	  
 230	  
MUC1-ST binding to Siglec-9 induces MEK-ERK activation  231	  
To investigate the intracellular effects of MUC1-ST binding we first assessed whether 232	  
MUC1-ST was able to induce the phosphorylation of the inhibitory ITIM motif of 233	  
Siglec-9, thereby inducing intracellular inhibitory signals12.  We hypothesized that this 234	  
possibility was likely as the repeated glycans found on MUC1 should be able to 235	  
crosslink Siglec-9. Surprisingly, instead of promoting phosphorylation, we found 236	  
MUC1-ST inhibited the resting phosphorylation of Siglec-9 ITIM in monocytes and 237	  
macrophages (Fig. 6a,b). Importantly, antibody-induced crosslinking of Siglec-9 did 238	  
induce phosphorylation (Fig. 6a). Furthermore, phosphorylation of SHP-1, which is 239	  
recruited by phosphorylated Siglec-9 (ref. 12), was not observed after MUC1-ST 240	  
binding to Siglec-9 on primary monocytes (Fig. 6c). However, phosphorylation of 241	  
SHP-1 was observed when Siglec-9 was activated via antibody cross-linking. No 242	  
activation of SHP-2 was observed (data not shown). This finding is in contrast to the 243	  
engagement of Siglec-9 with other, yet unknown, ligands present on tumor cells, 244	  
where recruitment of SHP-1 was observed15. Moreover, in a murine tumor model 245	  
Siglec-E, the murine Siglec with the most similarity to human Siglec-9, was 246	  
associated with a decrease in alternatively activated macrophages15. Engagement of 247	  
Siglecs has also been show to inhibit calcium flux37,38. We therefore investigated the 248	  
triggering of a calcium flux when MUC1-ST engaged Siglec-9. When monocytes or 249	  
macrophages were treated with MUC1-ST a calcium flux was induced that peaked at 250	  
	  30 s (Fig. 6d). This calcium flux was completely dependent on the engagement of 251	  
Siglec-9 by MUC1-ST (Fig. 6e). A calcium flux was also observed when monocytes 252	  
and T47D cells came into contact (Fig. 6f). This response could be inhibited by the 253	  
Siglec-9 antibody and was not seen when T47D cells expressed normal branched 254	  
core-2 glycans (Fig. 6f).  255	  
 256	  
As binding of MUC1-ST to Siglec-9 did not induce phosphorylation associated with 257	  
inhibitory signaling but rather induced a calcium flux, which is associated with 258	  
activating signals38, we investigated the downstream signaling after MUC1-ST 259	  
binding to Siglec-9. To explore this possibility, the production of PAI-1 and M-CSF 260	  
from MUC1-ST–educated monocytes and macrophages was assayed. As expected, 261	  
the secretion of PAI-1 and M-CSF could be significantly inhibited by calcium channel 262	  
inhibitor verapamil (Fig. 6g-j). Intracellular calcium flux can lead to activation of the 263	  
MEK-ERK pathway38. When monocytes or macrophages were incubated with MUC1-264	  
ST in the presence of the highly selective MEK inhibitor PD98059 (ref. 39), secretion 265	  
of PAI-1 and M-CSF was significantly inhibited as compared to monocytes and 266	  
macrophages incubated with MUC1-ST without the inhibitor (Fig. 6g-j). Moreover, 267	  
the repression of T cell proliferation by MUC1-ST–treated macrophages could be 268	  
partially overcome when MEK signaling was inhibited in the macrophages (Fig. 6k). 269	  
Thus we have identified an activating role for Siglec-9 upon MUC1-ST binding. 270	  
 271	  
 272	  
 273	  
 274	  
Discussion 275	  
 276	  
The majority of solid tumors contain infiltrating immune cells that are unable to 277	  
eliminate the tumor and, in many cases, promote tumor progression1. Tumor-278	  
associated macrophages are some of the most abundant immune cells to be found in 279	  
tumors, their presence correlating with metastasis and poor prognosis35,36,40,41. It has 280	  
been proposed that for tumors to thrive they need to produce factors that can recruit 281	  
and educate monocytes and repolarize resident macrophages into TAMs41. Here we 282	  
have identified MUC1-ST as a myeloid modulating factor and as a driver of TAM 283	  
formation demonstrated by the increased expression of CD206, CD163, IDO and PD-284	  
L1. MUC1-ST binding to Siglec-9 can increase expression of PD-L1 by macrophages 285	  
is an important observation, as immune checkpoint inhibitors are showing extremely 286	  
promising results in the clinic42. The degree of increase in expression of PD-L1 does 287	  
	  differ with the healthy donors and ranges from 1.5-fold to over 7-fold. Highly relevant 288	  
to this observation is that even modest effects on the expression of PD-L1 can lead 289	  
to tumor regression in murine models43 so changes up to 7 fold have the potential to 290	  
be highly relevant to tumor growth. Additionally, these macrophages with a TAM-like 291	  
phenotype can inhibit the proliferation and activation of CD8+ T cells. However the 292	  
reduction in the proliferation of the T cells seen in our system does not appear to be 293	  
due to the upregulation of PD-L1 on MUC1-ST educated macrophages as this could 294	  
not be inhibited by the PD-1 blocking antibody, pembroluzumab. The PD-1–PD-L1 295	  
checkpoint is not active in the initial T cell activation stage but rather acts on effector 296	  
cells recognizing antigen44. Although the PD-L1 expressed by MUC1-ST–educated 297	  
macrophages does not play a role in our in vitro assays where the proliferation of T 298	  
cells is not antigen-specific, this finding does not exclude a role in cancer when 299	  
tumors can be infilitrated with antigen-specific CD8+ T cells.  Moreover, engagement 300	  
of Siglec-9 on monocytes and macrophages by MUC1-ST induces the increased 301	  
secretion of proteins involved in disease progression. Thus. this MUC1-ST–Siglec-9 302	  
axis plays an important role in orchestrating a tumor-permissive environment.  303	  
 304	  
Aberrant glycosylation is a hallmark of cancer often resulting in increased 305	  
sialylation3,4,6, which has been shown to result in engagement of Siglecs14-16. 306	  
Individual Siglecs (except for Siglec-4) are expressed by different subset of cells 307	  
within the immune system leading to an overlapping and complex pattern of 308	  
expression11. Siglec-9 is expressed by macrophages and monocytes, as well as by 309	  
neutrophils, some B cells, a subset of T cells and a subset of NK cells. Ligands for 310	  
Siglec-7 and Siglec-9 have been demonstrated on tumor cells14,15 and their 311	  
engagement shown to inhibit NK activity14,16. When tumor cells were incubated with 312	  
neutrophils, the activation of the neutrophils was inhibited in a Siglec-9 dependent 313	  
manner with increased killing of tumor cells in the presence of a Siglec-9 blocking 314	  
antibody15. Mucins carry a very large number of O-linked glycans, the composition of 315	  
which changes with malignancy resulting in the expression of shorter sialylated 316	  
glycans4 with the potential to engage Siglecs. MUC16 has been identified as a ligand 317	  
for Siglec-9 (ref. 45), as have mucins isolated from a colon carcinoma cell line46. 318	  
MUC1 however is the most widely expressed mucin in cancers derived from 319	  
epithelial cells (adenocarcinomas) and the MUC1-ST glycoform is a dominant 320	  
surface feature. MUC1 carrying undefined glycans could bind to Siglec-9 resulting in 321	  
increased MUC1 signaling and growth of the MUC1-expressing tumor cells in vitro. 322	  
Infiltration of Siglec-9–expressing cells into MUC1-expressing tumors was observed 323	  
in vivo17.  However, this study did not investigate the effect on the immune cells of 324	  
	  Siglec-9 engagement by MUC1. The availability of purified recombinant MUC1 325	  
carrying defined glycans18 has here allowed its use as a ligand to study the effects on 326	  
myeloid cells of MUC1-ST binding to Siglec-9. The effects observed with this soluble 327	  
MUC1-ST have been validated using the breast cancer cell line, T47D which 328	  
expresses endogenous MUC1 carrying the ST glycan20.  329	  
MUC1 can also be expressed by activated, but not resting, T cells, although this level 330	  
of expression is at least 50 times lower than that expressed by breast cancer cells47. 331	  
MUC1 has also been seen on macrophages and dendritic cells. However, the O-332	  
linked glycosylation pattern of these cells changes with the activation state48,49 with 333	  
activated T cells carrying core 2 glycans rather than the sialylated core 1 glycans 334	  
(ST) that we show here binds Siglec-9.  335	  
 336	  
In contrast to classical Siglec engagement, which results in the recruitment and 337	  
activation of the phosphatases SHP-1 or SHP-2 (ref. 12), Siglec-9 engagement by 338	  
MUC1-ST does not induce phosphorylation of this Siglec or SHP-1, but induces the 339	  
transmission of activating signals. MUC1-ST binding to Siglec-9 on monocytes and 340	  
macrophages induced changes that would impact on the microenvironment to 341	  
promote tumor growth thereby acting as an immuno-modulator.  The mechanism 342	  
involved was demonstrated to be via the induction of a calcium flux leading to 343	  
activation of the MEK-ERK pathway. Understanding the mechanisms that contribute 344	  
to immune suppression by myeloid cells may help to develop new myeloid 345	  
checkpoint inhibitors, such as anti-Siglec-9 immunotherapy. 346	  
 347	  
The expression of the sialyltransferase ST3Gal-I is responsible for the addition of the 348	  
sialic acid to the core 1 glycan forming ST6. This enzyme is overexpressed in breast 349	  
and other carcinomas catalyzing the formation of short sialylated side chains. We 350	  
have shown that in breast cancers COX-2 can increase the expression of ST3Gal-I50. 351	  
The principal matabolite of COX-2 is PGE2 and COX-2 is induced by inflammatory 352	  
mediators (e.g. IL-6). Thus the chronic inflammation induced by MUC1-ST binding to 353	  
Siglec-9-positive myeloid cells would maintain the continued expression of the 354	  
MUC1-ST glycoform via induced expression of COX-2. This positive feedback loop 355	  
would maintain the induction of TAMs and the continued modulation of the 356	  
microenvironment (Supplementary Fig. 3). Thus we have determined a vital function 357	  
for aberrant O-linked glycosylation in tumor growth and progression. 358	  
 359	  
 360	  
 361	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  FIGURE LEGENDS 
 
Figure 1 MUC1 carrying sialylated core-1 glycans (MUC1-ST) binds to primary 
monocytes and macrophages through Siglec-9. (a) Pooled flow cytometric analysis 
(MFI, mean fluorescence intensity) of isolated or differentiated immune subsets from 
healthy donors incubated with 10 µg/ml biotinylated MUC1-ST. (b) Flow cytometry 
histograms of MUC1-ST and non-sialylated MUC1-T binding to primary monocytes 
and monocyte-derived macrophages and (c,d) bar graphs summarizing the data from 
multiple independent donors (MUC1-Ungly, unglycosylated MUC1). . (e) U937 cells 
incubated with MUC1-ST or MUC1-T and visualized using fluorescent microscopy. (f) 
Pooled flow cytometric analysis (MFI) of monocytes binding to MUC1 glycoforms in 
the presence of Ca2+ or EDTA. (g) Binding of MUC1 glycoforms to Siglec fusion 
proteins. (h) Flow cytometry histograms of MUC1-ST binding to monocytes or 
macrophages after pre-incubation with anti-Siglec-9 or isotype control and (i) dot 
plots summarizing the data with monocytes from multiple independent donors. (j) 
Fixed T47D cells stained with human Siglec-9-IgG fusion or an anti-MUC1 (HMFG2). 
Scale bars represent 25 µm. Data are from 4 independent donors (a); N=11 
independent donors for MUC1-ST and MUC1-T, N=4 for MUC1-Ungly (c,d); 
Representative of 6 experiments showing the same results (e); N=3 independent 
donors (f); Representative of 2 experiments, each done in triplicate, statistics refer to 
the technical triplicates (g); Representative of 7 independent donors; N=7 
independent donors (i); Representative of 2 experiments showing similar results (j). 
Data shown are the mean and s.e.m. P = *<0.05, **<0.01, ***0.001, as determined by 
Student’s paired t-test (a,c,d,f,i),  or unpaired t-test (g). 
 
Figure 2 MUC1-ST induces monocytes to secrete factors associated with tumor 
progression in a Siglec-9-dependent manner. (a) The secretome from isolated 
primary monocytes treated with MUC1-ST clustered into functional groups. Figures 
represent fold change from untreated cells. Validation by ELISA of IL-6, M-CSF and 
PAI-1 released by primary monocytes in response to MUC1-ST, in a sialic acid 
(b,c,d) and Siglec-9 (e,f,g) dependent manner. (h) PAI-1 secreted by primary 
monocytes incubated with T47D cells and as a control T47D cells engineered to 
carry normal extended core 2 O-linked glycans (T47D (core 2)). (i) Nitric oxide 
release by monocytes after incubation with MUC1-ST in the presence or absence of 
anti-Siglec-9. Data is from 1 donor (a); N=19 independent donors for MUC1-ST and 
No MUC1, N=6 for MUC1-T (b); N=7 independent donors for MUC1-ST and No 
	  MUC1, N=3 for MUC1-T (c); N=8 independent donors for MUC1-ST and No MUC1, 
N=6 for MUC1-T (d); N=12 independent donors (e); N=4 independent donors (f); N=3 
independent donors (g); N=2 independent experiments with technical triplicates, 
statistics refer to technical triplicates (h). N=13 (no MUC1/MUC1-ST), N=4 
(isotype/anti-Siglec-9) (i).  
Data shown are the mean and s.e.m. P = *<0.05, **<0.01, ***0.001, as determined by 
Student’s paired t-test (b,c,d,e,f,g,i),  or unpaired t-test (h). 
 
Figure 3 MUC1-ST engagement of Siglec-9 during the differentiation of monocytes 
into inflammatory macrophages results in the generation of dysfunctional cells. (a) 
Flow cytometry histograms showing CD86 expression by LPS & IFNγ differentiated 
M-CSF macrophages after treatment with MUC1-ST on day 0 in the presence of 
isotype control or anti-Siglec-9 or anti-IL-6Rα and (b) bar graphs summarizing the 
data from multiple independent donors. (c) IL-12 p70 release from macrophages 
treated as in (a,b). (d,e,f) Day 0 MUC1-ST treated M-CSF macrophages were co-
cultured with autologous CD8+ or CD4+ T cells in the presence of anti-CD3 and anti-
CD28 beads and proliferation (d) or expression of CD69 (e) were measured by flow 
cytometric analysis. (f) Density plots showing % of CD69+CD25+ CD8+ T cells co-
cultured with autologous M-CSF macrophages treated with MUC1-ST and antibody 
(isotype, anti-Siglec-9 or anti -L-6Rα). N=3 independent donors (b,c,d,e); 
Representative data from 3 independent donors showing similar results (f). Data 
shown are the mean and s.e.m. P = *<0.05, **<0.01, as determined by Student’s 
paired t-test (b,c,d,e). 
 
Figure 4 MUC1-ST educated M-CSF macrophages secrete factors associated with 
tumor progression in a Siglec-9 dependent manner. (a) The secretome from 
monocyte derived M-CSF macrophages treated MUC1-ST clustered into functional 
groups and compared to the MUC1-ST educated monocyte signature. Figures 
represent fold change from untreated cells.  (b-g) Validation by ELISA of M-CSF, 
PAI-1, EGF released by M-CSF macrophages in response to MUC1-ST, in a sialic 
acid (b,c,d and Siglec-9 (e,f,g) dependent manner. (h) PAI-1 secreted by 
macrophages incubated with T47D cells and as a control T47D cells engineered to 
carry normal extended core 2 O-linked glycans (T47D (core 2)). N=3 independent 
donors (b,c,d,e,f,g); Representative of 2 independent experiments with the statistical 
analysis performed on technical triplicates (h). Data shown are the mean and s.e.m. 
	  P = **<0.01, ***0.001, as determined by Student’s paired t-test (b,c,d,e,f,g),  or 
unpaired t-test (h). 
 
Figure 5 MUC1-ST educated M-CSF macrophages differentiate into tumor-
associated macrophages (TAMs). (a) Flow cytometry histograms showing CD206, 
CD163 and PD-L1 expression on macrophages treated with MUC1-ST ± anti Siglec-
9 or isotype as indicated. Numbers refer to % positive cells and, in brackets, to 
corrected MFI. (b,c) Normalised (actin) IDO mRNA expression from (b) GM-CSF or 
(c) M-CSF macrophages treated with MUC1-ST ± anti Siglec-9 or isotype. Data 
displayed as fold change with respect to cells treated with isotype control alone. (d) 
Concentration of kynurenine in the supernatant of M-CSF macrophages treated with 
MUC1-ST ± anti-Siglec-9 or isotype. (e,f) M-CSF macrophages treated with MUC1-
ST ± anti Siglec-9 or isotype were co-cultured with labeled allogeneic CD8+ T cells 
and (e) proliferation or (f) IFNγ secretion measured by flow cytometry and ELISA 
respectively. (g,h) M-CSF macrophages treated with MUC1-ST were co-cultured with 
labeled allogeneic CD8+ T cells in the presence of anti-PD-1 (pembroluzumab) or 
isotype and (g) proliferation or (h) IFNγ secretion measured by flow cytometry and 
ELISA respectively. % CD8+ T cell proliferative response to allogeneic M-CSF 
macrophages is shown in black and to MUC1-ST treated allogeneic macrophages in 
red. Representative experiment of two giving similar results (a); N=2 independent 
experiments with 2 different donors, statistical analysis performed on technical 
triplicates (b,c); N=4 independent donors (d); N=3 independent donors (e,f); N=2 
donors different from 5e (g); N=3 donors different from 5f (h). P = *<0.05,  **<0.01, 
***0.001, as determined by Student’s paired t-test (d,e,h),  or unpaired t-test (b,c,f). 
 
Figure 6 MUC1-ST binding to myeloid cells via Siglec-9 leads to calcium flux and 
MEK/ERK activation. (a) Monocytes treated with MUC1-ST or cross-linked anti-
Siglec-9 were lysed in the presence of pervanadate and assayed for phospho-Siglec-
9. (b) Lysates from M-CSF macrophages treated with MUC1-ST or MUC1-T were 
assessed for the phosphorylation of Siglec-9 (top, phospho-Siglec-9; bottom, 
reference). (c) Lysates from MUC1-ST or cross-linked anti-Siglec-9 treated 
monocytes, were probed for SHP-1 and phospho-SHP-1 (d) Fluorescent calcium 
reporter labeled monocytes were treated with MUC1-ST or MUC1-T and calcium flux 
measured. (e) Calcium reporter labeled monocytes were treated with MUC1-ST ± 
anti-Siglec-9 or isotype or PMA, ionomycin; MFI measured at 60 seconds. (f) 
Calcium reporter labeled monocytes were co-cultured with T47D cells or T47D(core-
	  2) cells ± anti-Siglec-9 or isotype; MFI measured at 60 seconds. (g,h) Monocytes 
were treated with PD98059 or verapamil prior to MUC1-ST. Supernatants were 
assayed for (g) PAI-1 and (h) M-CSF. (i,j) Macrophages were treated as in g and h 
and supernatants assayed for (i) PAI-1 and (j) M-CSF. (k) Macrophages treated with 
MUC1-ST ± PD98059 were incubated with allogeneic labeled CD8+ T cells.  N=3 
independent donors (a); Representative of 2 experiments each using different donors 
(b); Representative of 2 independent donors, the statistical analysis done on 
technical triplicates (d,f);  N=3 independent donors (e,g,h,i,j); N=2, and the statistical 
analysis done on pooled duplicates from the two donors (k).  Data shown are the 
mean and s.e.m. P =*<0.05,  **<0.01, ***0.001, as determined by Student’s paired t-
test (a,e,g,h,i,j),  or unpaired t-test (f,k). 
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ON-LINE METHODS 1	  
 2	  
Isolation and differentiation of immune subsets. 3	  
Leukocytes cones were purchased from the National Blood Transfusion Service 4	  
(NBTS, Tooting, UK) and centrifuged on a Ficoll gradient (Ficoll-Paque PREMIUM, 5	  
GE Healthcare) at 400g. CD14+, CD19+, CD8+, CD4+ cells were isolated from PBMCs 6	  
using microbeads (MACS system; Miltenyi Biotech) according to the manufacturer’s 7	  
instructions. Purity was assessed at >95% by staining with relevant antibodies. For 8	  
ethical reasons, no information was supplied with these leukocyte cones. For the PD-9	  
L1 inhibition experiments blood was taken with informed consent from healthy 10	  
volunteers under ethical approval obtained for the National Research Ethics Service, 11	  
South East Research Ethics Committee 1, study number 09/H0804/92. 12	  
To differentiate monocytes into macrophages, CD14+ cells were plated at a 13	  
concentration of 1 × 106/ml in AIM V medium (Lonza) with either 50 ng/ml 14	  
recombinant human M-CSF or 50 ng/ml recombinant human GM-CSF (Bio-Techne). 15	  
The cytokines were added every 3 days. The cells were incubated at 37 °C, 5% CO2 16	  
for 7 days to fully differentiate, before being characterized as macrophages via 17	  
phenotypic flow cytometric analysis. To further differentiate the macrophages the 18	  
cells were treated with LPS and IFN-γ for 48 h to give M(LPS+IFN-γ)30. 19	  
To differentiate monocytes into dendritic cells (moDC), CD14+ cells were plated at a 20	  
concentration of 1 × 106/ml in AIM V medium with 1500 U/ml recombinant human IL-21	  
4 (Bio-Techne) and 400 U/ml human GM-CSF (Bio-Techne) for 6 days to fully 22	  
differentiate, before being characterised as immature DCs via phenotypic flow 23	  
cytometric analysis (Epics XL, Beckman Coulter or FACSCalibur, BD Biosciences 24	  
plus WinMDI or Cellquest software). MoDCs were matured using 1 µg/ml LPS for 24 25	  
h.  26	  
 27	  
Production of recombinant human MUC1 glycoforms. 28	  
Recombinant secreted MUC1 consisting of 16 tandem repeats carrying sialylated 29	  
core 1 and fused to mouse Ig was produced in CHO cells as described18. 30	  
Concentrated supernatant was treated with 10 mg trypsin per mg MUC1-ST-IgG for 2 31	  
h (MUC1 tandem repeats are not sensitive to trypsin digestion) to remove the Ig. The 32	  
treated supernatant was applied to a HiPrep 16/10 Q FF anion exchange column, 33	  
which was washed to remove the unbound material with 20 column volumes of 50 34	  
mM Tris-HCl pH 8.0. The MUC1-ST was eluted as described18. The purity of the 35	  
product was determined by giving a negative result in a mouse IgG ELISA, silver 36	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staining of SDS PAGE and an amino acid composition which was comparable to that 37	  
reported previously18. All batches of purified MUC1-ST were tested for lack of 38	  
endotoxin using the LAL assay (Lonza) as per manufacturer’s instructions; TGF-β 39	  
using an ELISA (Bio-Techne) as per manufacturer’s instructions; Protease activity 40	  
using the casein cleavage assay (Pierce/ThermoFisher) as per manufacturer’s 41	  
instructions. The product was quantitated either by amino acid analysis (Alta 42	  
Bioscience) or using an HMFG2:HMFG2 sandwich ELISA against a previously 43	  
quantified batch. It is important to note that the endotoxin concentrations of MUC1-44	  
ST 0.004-0.002 EU/µg, was well below the limits required for immunological 45	  
experiments.  46	  
MUC1 carried core 1 glycans without sialylation, MUC1-T, was produced by dialyzing 47	  
purified MUC1-ST in 50 mM NaAc pH 6.0, 4 mM CaCl2 O/N at 4 °C, and then treating 48	  
with 0.1 5 U/mg neuraminidase (NA) on agarose beads (Sigma) O/N at 23 oC and 49	  
then dialyzed against PBS O/N. Cleavage of sialic acids was measured by 50	  
HMFG2:lectin ELISA. Briefly 1 µg/ml HMFG2 in PBS was bound to plastic O/N, 51	  
before being blocked (1% BSA in PBS) and the samples (pre and post NA treatment) 52	  
were loaded and incubated at 23 oC for 2 h. Sugars were analyzed using 1 µg/ml 53	  
biotinylated PNA (binds exposed galactose residues; does not bind ST) and 5 µg/ml 54	  
biotinylated MAA (binds α-2,3 linked sialic acids; does not bind T). Unglycosylated 55	  
MUC1 was produced in CHO ldlD cells as described previously8 without the addition 56	  
of 1 mM GalNAc to the growth medium. Biotinylation of these glycoforms was 57	  
performed as described previously8. 58	  
 59	  
Binding of MUC1 glycoforms to cells. 60	  
1 × 105 isolated / differentiated cells at 5 × 105 cells per ml were incubated for 4 h on 61	  
ice with 10 µg of the appropriate biotinylated recombinant MUC1 glycoform in 0.5% 62	  
BSA in PBS. Cells were washed in 0.5% BSA in PBS before 1:200 SAPE (Life 63	  
Technologies) was added for 30 min on ice. Cells were washed and analyzed by flow 64	  
cytometry or fluorescent microscopy (after cytospin). Blocking antibodies were used 65	  
at 10 µg/ml. 66	  
 67	  
Functional experiments 68	  
For functional experiments, isolated monocytes or monocyte derived macrophages 69	  
were treated with 100 µg/106 cells MUC1-ST or MUC1-T (MUC1-ST with the sialic 70	  
acid removed) for 4 h at 4 °C, washed and incubated at 37 °C for 48 h in AIM-V 71	  
serum-free media. 72	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To investigate the role of MUC1-ST on the differentiation of monocytes to 73	  
macrophages, monocytes were incubated with MUC1-ST for 4 h at 4 °C and then 74	  
differentiated in the presence of M-CSF. For blocking binding with anti-Siglec-9 75	  
antibody, monocytes were treated with 10 µg/106 anti-Siglec-9 or isotype control 76	  
before being incubated with MUC1-ST for 4 h at 4 °C and then differentiated in the 77	  
presence of M-CSF. To inhibit the action of IL-6, IL-6Rα antibody, 10 µg/ml 78	  
Tocilizumab, was added every two days. 79	  
 80	  
 81	  
Binding of MUC1 glycoforms to recombinant Siglecs. 82	  
Mouse anti human IgG was bound to plastic O/N and the plate was blocked using 83	  
1% BSA in PBSa. Recombinant human Siglec (3, 5, 7, 8, 9 and 10) fusion proteins 84	  
were added at 2 µg/ml for 2 h. After incubation with 2 µg/ml biotinylated MUC1 85	  
glycoforms for 4 h, O.D was measured after the addition of streptavidin-HRP and 86	  
substrate. 87	  
 88	  
MLR and stimulation with anti-CD3 and anti-CD28. 89	  
MUC1-ST educated macrophages were co-cultured for 48 h with either autologous 90	  
CD8+ T cells  (‘AMLR’), in the presence of anti-CD3/CD28 beads, or allogeneic CD8+ 91	  
T cells (MLR) labeled with eFluor® 670 (eBioscience) at a 1:1 ratio. eFluor® 670 is a 92	  
protein dye that binds to primary amines and was used to measure proliferation 93	  
through loss of fluorescence intensity by 2 after one division.  CD8+ T cell 94	  
proliferation, CD69/CD25 cell surface expression and IFN-γ production were 95	  
measured using flow cytometry and ELISA (eBioscience). 96	  
For blocking PD-1, 10 µg/ml Pembroluzumab or human IgG4 isotype control was 97	  
added to isolated CD8+ T for 10 min before co-culturing with MUC1-ST educated 98	  
macrophages for 72 h. After this period supernatant was taken for IFN-γ 99	  
measurements.  100	  
 101	  
Calcium flux. 102	  
Monocytes pre-labeled with a intracellular calcium reporter (Fluo-4; Life 103	  
Technologies) were treated with MUC1-ST, MUC1-T (100 µg/106 cells) or T47D 104	  
monolayer, for 4 h at 4 °C. The cells were brought up to 37 °C and calcium flux was 105	  
measured at 530 nm using a plate reader at the indicated time points. Where not 106	  
indicated, time point was 60 s. 107	  
 108	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Phospho-Siglec 9 ELISA. 109	  
Anti-human Siglec 9 was plated O/N on plastic before being blocked with 1% BSA in 110	  
PBS. Clarified supernatant was added and incubated for 2 h. After incubation with 1 111	  
µg/ml biotinylated anti phospho-tyrosine, O.D (450 nm) was measured after the 112	  
addition of streptavidin-HRP and substrate. 113	  
 114	  
Cell lines, antibodies and other reagents. 115	  
T47D cells obtained for the originator were cultured in RPMI 1640 (Lonza) 116	  
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine 117	  
and 10% heat-inactivated FCS (all Life Technologies). To maintain the cells 118	  
authenticity cells were frozen as soon as possible after arrival to create a master 119	  
bank. Cells were kept in culture for no longer than 10 weeks and expression of 120	  
MUC1 was regularly checked. T47D cells transfected with C2GNT1 as described 121	  
previously20 were additionally cultured with 500 µg/ml G418. All cell lines were kept in 122	  
culture for no longer than 12 weeks at a time. 123	  
 124	  
Cell phenotype staining and neutralization was performed using the antibodies 125	  
described in Supplementary Table 2. Cells were suspended in PBS + 0.5% BSA (2 126	  
× 105 cells/100 µl/sample) and incubated with MoAbs according to the manufacturer's 127	  
instructions. At least 1 × 104 events were evaluated using either Epics XL, (Beckman 128	  
Coulter) or FACSCalibur (BD Biosciences) flow cytometers. Analysis was performed 129	  
using either WinMDI or Cellquest software. 130	  
 131	  
Biotinylated polyacrylamide-ST (PAA-ST) was obtained from Glycotech. This is a 132	  
synthetic carbohydrate probe in which the carbohydrate is incorporated into a 133	  
polyacrylamide matrix thereby creating a 30 kDa multivalent polymer. The saccharide 134	  
content is 20% and there are a nominal 20 trisaccharides per PAA and 4 biotin 135	  
molecules. 10 µg/ml biotinylated PAA-ST was bound to monocytes and the binding 136	  
visualized by flow cytometry using streptavidin-PE.  137	  
 138	  
 139	  
Protein arrays. 140	  
Isolated monocytes were treated with 100 µg/106 cells MUC1-ST for 4 h at 4 °C, 141	  
washed and incubated at 37 °C for 48 h in AIM-V serum-free media. Supernatant 142	  
was taken and cytokine production was assessed using an antibody capture protein 143	  
array (Bio-Techne).  Differentiated M-CSF macrophages were treated with 100 144	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µg/106 cells MUC1-ST for 4 h at 4 °C, washed, before being rapidly brought up to 145	  
37 °C for 5 min in PBS. Cells were immediately lysed on ice and clarified supernatant 146	  
was used on a 59-phospho immunoreceptor array (Bio-Techne) according to 147	  
manufacturer’s instructions. 148	  
 149	  
Nitric oxide  150	  
Supernatant was assessed using the Griess method according to the manufacturer’s 151	  
instructions (Biotium). 152	  
 153	  
Kynurenine.  154	  
60 µl supernatant was mixed with 30 µl 30% trichloroacetic acid (TCA) and incubated 155	  
for 30 min at 50 °C. The supernatant was spun at 3000g and 50 µl was taken and 156	  
mixed with 50 µl freshly prepared Ehrlich Reagent (2% p-157	  
dimethylaminobenzaldehyde in glacial acetic acid). After 10mins optical density was 158	  
measured at 492 nm. Concentrations were calculated against a kynurenine standard 159	  
curve.  160	  
 161	  
ELISAs 162	  
ELISAs for IL-6, IL-12p70, TGF-β1, PAI-1, M-CSF, EGF, SHP2, phospho-SHP2 163	  
(Biotechne) were all carried out as per manufacturers instructions.  164	  
 165	  
Immunoblots 166	  
Lysates were run on SDS PAGE (10% gel) before being transferred, blocked and 167	  
probed with anti-SHP1 (Santa Cruz) or anti phospho SHP1 (Abcam) and appropriate 168	  
secondary. 169	  
 170	  
RNA isolation and qPCR. 171	  
RNA was isolated from cells using RNeasy Mini kits (Qiagen).  Contaminating DNA 172	  
was removed with a DNase-free kit (Ambion). cDNA was synthezied using a 173	  
SuperScript VILO kit (Invitrogen). Quantitative real-time PCR (qPCR) was carried out 174	  
with cDNA using SYBR green-containing mastermix (Primer Design) using PUM1 as 175	  
a reference gene. The following oligonucleotides were used to test the expression of 176	  
IDO1: F: 5′-ACAGACCACAAGTCACAGCG-3′  R: 5′-GGACATCTCCATGACCTTTG-177	  
3′  and PUM1: F:	   5′- GATTATTCAGGCACGCAGGT-3′  R:	   5′-178	  
AGCAGCGCTGATGATGTATG-3′. 179	  
 180	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Statistical Analyzes 181	  
Sample size choice: The majority of the assays performed used either ≥ 3 donors to 182	  
overcome donor variability.  183	  
Randomization and blinding statement: The majority of assays performed used blood 184	  
from healthy volunteers. For all assays, excluding the PD-1 inhibition assay, these 185	  
volunteers were provided by the NHS, with no associated information and were 186	  
therefore blinded. There was therefore no need for randomisation of these donors.  187	  
Exclusion criteria: No ‘outlier’ tests were performed on any of our datasets.  188	  
 189	  
 190	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